title: Type 2 Diabetes Mellitus Is Associated with Strongyloides stercoralis Treatment Failure in Australian Aboriginals.
abstract: OBJECTIVE
  To explore the efficacy of ivermectin in the treatment of serologically diagnosed cases of Strongyloides stercoralis (S. stercoralis) infection in an Aboriginal community and to describe factors that may influence the outcome of treatment.
  
  
  METHODS
  Longitudinal study of a group of 92 individuals with serologically diagnosed S. stercoralis treated with ivermectin and followed up over a period of approximately 6 months. Main outcomes were serological titers pre and post treatment, diabetic status, and duration of follow up.
  
  
  RESULTS
  Treatment success was achieved in 62% to 79% of cases dependent on the methods employed for the diagnosis of infection and assessment of treatment outcome. Type 2 Diabetes Mellitus (T2DM) was found to be significantly associated with treatment failure in this group for two of the three methods employed.
  
  
  CONCLUSIONS
  Ivermectin has been confirmed as an effective treatment for S stercoralis infection in this setting. T2DM appears to be an independent risk factor for treatment failure in this population, and plausible mechanisms to explain this observation are presented.
authors: Kimberley Aboriginal Medical Council, Broome, Western Australia, Australia; James Cook University, Cairns Campus, Smithfield, Queensland, Australia.
authors: Russell
authors: R
authors: Hays
authors: Centre for Research Excellence in Chronic Disease Prevention, The Cairns Institute, James Cook University, Cairns Campus, Smithfield, Queensland, Australia; Sansom Institute of Health Service Research and School of Nursing and Midwifery, University of South Australia City East Campus, Adelaide, South Australia, Australia.
authors: Adrian
authors: A
authors: Esterman
authors: Centre for Chronic Disease Prevention, Australian Institute of Tropical Health and Medicine, College of Public Health, Medical and Veterinary Sciences, James Cook University, Cairns, Queensland, Australia; School of Population Health, University of South Australia, Adelaide, South Australia, Australia.
authors: Robyn
authors: R
authors: McDermott
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000977:Antiparasitic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001315:Australia / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000453:epidemiology / Q000208:ethnology; D006801:Humans; D007559:Ivermectin / Q000008:administration & dosage / Q000627:therapeutic use*; D008137:Longitudinal Studies; D017171:Strongyloides stercoralis / Q000187:drug effects*; D013322:Strongyloidiasis / Q000188:drug therapy*; D017211:Treatment Failure
chemical_list: D000977:Antiparasitic Agents; D007559:Ivermectin